Clinical Expert Available To Discuss Eteplirsen, First Approved Treatment For Duchenne Muscular Dystrophy

Option Care, selected as a contracted provider, offers insight on the expanding role of pharmacists in the treatment and care of those managing and living with this disorder

Yesterday, September 19 the U.S. Food and Drug Administration approved Eteplirsen, manufactured by Sarepta Therapeutics for the treatment of Duchenne Muscular Dystrophy (DMD). DMD, the most common form of muscular dystrophy, is a debilitating and ultimately fatal inherited disorder that primarily affects boys.

Kendra Curry, PharmD, Corporate Director, Specialty Infusion Programs at Option Care is available to discuss the following:

• What the availability of this drug means to patients and their families.
• How Option Care’s high-touch, high-skilled nursing and pharmacy support services will help patients with side effect management and medication adherence.

Eteplirsen will be administered to patients by intravenous (IV) infusion. Option Care was selected as a contracted provider by Sarepta Therapeutics because it is one of the nation’s leading providers of home and alternate treatment site infusion services. Option Care has a staff of more than 1,800 clinical experts, including pharmacists, more than 1,200 infusion nurses and more than 100 registered dietitians. This multidisciplinary team of specially trained clinicians provides individualized patient care plans, clinical monitoring of each infusion and comprehensive patient and caregiver education.